| Basics |
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of therapies for people with rare debilitating diseases, chronic neuromuscular and neurological diseases.
|
| IPO Date: |
October 5, 2001 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.96B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.14 | 3.28%
|
| Avg Daily Range (30 D): |
$0.46 | 2.00%
|
| Avg Daily Range (90 D): |
$0.44 | 1.99%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.83M |
| Avg Daily Volume (30 D): |
.95M |
| Avg Daily Volume (90 D): |
.95M |
| Trade Size |
| Avg Trade Size (Sh.): |
156 |
| Avg Trade Size (Sh.) (30 D): |
54 |
| Avg Trade Size (Sh.) (90 D): |
58 |
| Institutional Trades |
| Total Inst.Trades: |
2,005 |
| Avg Inst. Trade: |
$2.67M |
| Avg Inst. Trade (30 D): |
$2.87M |
| Avg Inst. Trade (90 D): |
$3.43M |
| Avg Inst. Trade Volume: |
.23M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.34M |
| Avg Closing Trade (30 D): |
$4.58M |
| Avg Closing Trade (90 D): |
$5.52M |
| Avg Closing Volume: |
279.2K |
|
|
|
|
| Financials |
| |
TTM |
Q4 2024 |
FY 2024 |
|
Basic EPS
|
$1.38
|
$.46
|
$1.38
|
|
Diluted EPS
|
$1.31
|
$.44
|
$1.31
|
|
Revenue
|
$ 491.73M
|
$ 141.82M
|
$ 491.73M
|
|
Gross Profit
|
$ 422.89M
|
$ 120.18M
|
$ 422.89M
|
|
Net Income / Loss
|
$ 163.89M
|
$ 55.94M
|
$ 163.89M
|
|
Operating Income / Loss
|
$ 195.12M
|
$ 62.84M
|
$ 195.12M
|
|
Cost of Revenue
|
$ 68.85M
|
$ 21.64M
|
$ 68.85M
|
|
Net Cash Flow
|
$ 379.92M
|
$ 75.22M
|
$ 379.92M
|
|
PE Ratio
|
0.00
|
|
|
|
